Association of cytogenetic abnormalities with detection of BCR‐ABL fusion transcripts in children with T‐lineage lymphoproliferative diseases (T‐ALL and T‐NHL)

Nigro, Luca Lo; Sainati, Laura; Mirabile, Elena; Lanciotti, Marina; Poli, Amelia; Leszl, Anna; Basso, Giuseppe

doi:10.1002/pbc.10453

Cited by 10 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The unusual characteristic of our BCR/ABL positive patients can be considered to be predominantly of T-lineage morphology (4/7 patients). The BCR/ABL rearrangement in T-lineage ALL is a very rare event, but singular cases have been reported in adult ALL and also in de novo and relapsed childhood ALL [11][12][13]. Our findings, as well as those previously reported, define BCR/ABL positive ALL as a heterogeneous disease concerning lineage involvement.…”

Section: Discussionsupporting

confidence: 61%

Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia

Lazić

Tos̆ić²,

Dokmanović

et al. 2009

Med Oncol

View full text Add to dashboard Cite

Contemporary protocols ensure high-remission rate and long-term free survival in children with acute lymphoblastic leukemia (ALL), but small percentage of patients is still incurable. Molecular genetic methods helped to establish submicroscopic classification as well as minimal residual disease follow-up, considered to be responsible for relapse. Our study enrolled 70 pediatric patients with de novo ALL, analyzed using reverse transcriptase-polymerase chain reaction for the presence of four major risk-stratifying translocations (BCR/ABL, MLL/AF4, TEL/AML1, and E2A/PBX1). Bone marrow samples were collected at diagnosis, at the end of induction phase, and after intensive chemotherapy with the aim to establish the correlation between chromosomal aberration, clinical features, and treatment response. Presenting the results of this study, we offer another evidence of variable incidence and clinical characteristics of ALL subtypes.

show abstract

Section: Discussionsupporting

confidence: 61%

Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia

Lazić

Tos̆ić²,

Dokmanović

et al. 2009

Med Oncol

View full text Add to dashboard Cite

show abstract

“…We report that, even in the absence of peripheral blasts and BM involvement, MD was detected by PCR in at least one of the diagnostic staging PB and/or BM specimens. Our ability to capture 100% of one of the staging/diagnostic specimens and identify a marker that can be used to assess MD may bode well as a clinical tool for future prospects (Lo Nigro et al , 2004; Agsalda et al , 2009; Lovisa et al , 2009). As the current study was limited to Group B Stage III/IV patients, similar investigations in children and adolescents with Group A and Group B Stage I/II B‐NHL remain to be completed.…”

Section: Discussionmentioning

confidence: 99%

Minimal disease assessment in the treatment of children and adolescents with intermediate‐risk (Stage III/IV) B‐cell non‐Hodgkin lymphoma: a children’s oncology group report

et al. 2011

View full text Add to dashboard Cite

Summary Children/adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL) have an excellent prognosis but relapses still occur. While chromosomal aberrations and/or clonal immunoglobulin (Ig) gene rearrangements may indicate risk of failure, a more universal approach was developed to detect minimal disease (MD). Children/adolescents with intermediate-risk B-NHL were treated with French-British-American/Lymphome Malins de Burkitt 96 (FAB/LMB96) B4 modified chemotherapy and rituximab. Specimens from diagnosis, end of induction (EOI), and end of therapy (EOT) were assayed for MD. Initial specimens were screened for IGHV family usage with primer pools followed by individual primers to identify MD. Thirty-two diagnostic/staging specimens screened positive with primer pools and unique IGHV family primers were identified. Two patients relapsed; first relapse (4 months from diagnosis) was MD-positive at EOI, the second (36 months from diagnosis) was MD-positive at EOT. At EOI, recurrent rates were similar between the MRD-positive and MRD-negative patients (p=0.40). At EOT, only 13/32 patients had MRD data available with 1 relapse in the MRD-positive group and no recurrences in the MRD-negative group (p=0.077). The study demonstrated molecular-disseminated disease in which IgIGHV primer pools could be used to assess MD. This feasibility study supports future investigations to assess the validity and significance of MD screening in a larger cohort of patients with intermediate-risk mature B-NHL.

show abstract

“…Patients often present with bulky mediastinal disease related to involvement of the thymus [6]. The Ph1 chromosome has rarely been reported in T-lineage ALL and the clinical relevance of this translocation in T-ALL is currently unknown [3,7,8,9,10,11,12]. …”

Section: Introductionmentioning

confidence: 99%

Philadelphia-Chromosome-Positive T-Lymphoblastic Leukemia: Acute Leukemia or Chronic Myelogenous Leukemia Blastic Crisis

et al. 2005

View full text Add to dashboard Cite

The Ph1 chromosome has rarely been reported in T-lineage acute lymphoblastic leukemia (T-ALL), and the clinical relevance of this translocation in T-ALL is currently unknown. In chronic myelogenous leukemia (CML) some data indicate derivation of T-cells from the leukemic clone and only a few cases of T-derived blastic crisis have been reported and quite often disputed. Particularly in cases identified initially in blastic crisis it may be difficult to distinguish those from Ph1-positive T-ALL. We herein report 2 patients who presented with a clinical picture of Ph1-positive T-ALL and who raised a differential diagnosis from T-cell blastic crisis of CML. We review the literature and suggest clinical and laboratory features that can help in the diagnosis. According to our literature review, 23 cases of Ph1-positive T-ALL and 44 cases of T-cell blastic crisis of CML, including ours, were reported. Some major differences between the two entities could help in establishing a diagnosis of Ph1-positive T-cell blastic crisis of CML vs. Ph1-positive T-ALL: Male sex and younger age was more predominant in T-ALL. While in most cases of CML blastic crisis there was a history of CML there was no such history in the T-ALL cases. Medullary involvement with lymphoblastic leukemia was present in all cases of T-ALL but only in about half of the cases of CML blastic crisis. None of the CML-blastic crisis cases tested by RT-PCR showed the minor breakpoint transcript, while 2 cases with T-ALL had the minor breakpoint transcript and 1 had both transcripts. Combined morphologic and FISH analysis can help to distinguish between the two entities and was applied in one of our cases. Although both entities carry a severe prognosis, differentiating between them might have clinical relevance, especially in the imatinib era.

show abstract

Association of cytogenetic abnormalities with detection of BCR‐ABL fusion transcripts in children with T‐lineage lymphoproliferative diseases (T‐ALL and T‐NHL)

Cited by 10 publications

References 9 publications

Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia

Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia

Minimal disease assessment in the treatment of children and adolescents with intermediate‐risk (Stage III/IV) B‐cell non‐Hodgkin lymphoma: a children’s oncology group report

Philadelphia-Chromosome-Positive T-Lymphoblastic Leukemia: Acute Leukemia or Chronic Myelogenous Leukemia Blastic Crisis

Contact Info

Product

Resources

About